The FDA authorized a second booster of the Pfizer or Moderna COVID-19 vaccines for those age 50 and older and certain immunocompromised people.

Adults in England aged 50 years or older who received the bivalent BA.1 mRNA booster vaccine during the 2022 autumn campaign had substantially lower risks for COVID-related hospitalisation and death ...

Booster vaccines reduced the risk of COVID‑19–related hospitalization and death, according to a new study of over 3 million adults who had the autumn 2022 vaccine in England. The research led by the ...

Both the seasonal flu vaccine and the updated COVID-19 vaccine are recommended annually for nearly everyone ages 6 months and older to prevent severe respiratory illness, hospitalizations, and death.